Patents by Inventor Lynnie Lin TRZOSS

Lynnie Lin TRZOSS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11560391
    Abstract: The present disclosure relates to novel sulfonylurea compounds and related compounds useful in treating a disorder responsive to modulation of cytokines such as IL-1? and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: January 24, 2023
    Assignee: Genentech, Inc.
    Inventors: Jeffrey A. Stafford, James M. Veal, Lynnie Lin Trzoss, Christopher McBride, Richard M. Pastor, Steven Thomas Staben, Craig Stivala, Matthew Volgraf
  • Publication number: 20220306649
    Abstract: The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1? and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.
    Type: Application
    Filed: March 3, 2022
    Publication date: September 29, 2022
    Applicant: Genentech, Inc.
    Inventors: Jeffrey A. STAFFORD, James M. VEAL, Lynnie Lin TRZOSS, Christopher MCBRIDE
  • Publication number: 20210395268
    Abstract: The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1? and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.
    Type: Application
    Filed: January 25, 2021
    Publication date: December 23, 2021
    Applicant: Genentech, Inc.
    Inventors: Jeffrey A. STAFFORD, James M. VEAL, Lynnie Lin TRZOSS, Christopher MCBRIDE
  • Publication number: 20210261568
    Abstract: The present disclosure relates to novel sulfonylurea compounds and related compounds useful in treating a disorder responsive to modulation of cytokines such as IL-1? and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.
    Type: Application
    Filed: January 15, 2021
    Publication date: August 26, 2021
    Applicant: Genentech, Inc.
    Inventors: Jeffrey A. STAFFORD, James M. VEAL, Lynnie Lin TRZOSS, Christopher MCBRIDE, Richard M. PASTOR, Steven Thomas STABEN, Craig STIVALA, Matthew VOLGRAF
  • Publication number: 20210253596
    Abstract: The present disclosure relates to novel sulfonimidamide compounds and related compounds and their use in treating a disorder responsive to modulation of cytokines such as IL-1? and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.
    Type: Application
    Filed: January 15, 2021
    Publication date: August 19, 2021
    Applicant: Genentech, Inc.
    Inventors: Christopher MCBRIDE, Lynnie Lin TRZOSS, Amogh BOLOOR, Nadezda V. SOKOLOVA, Richard M. PASTOR, Steven Thomas STABEN, Craig STIVALA, Matthew VOLGRAF, Sarah M. BRONNER
  • Patent number: 11040985
    Abstract: The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1? and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: June 22, 2021
    Assignee: Genentech, Inc.
    Inventors: Jeffrey A. Stafford, James M. Veal, Lynnie Lin Trzoss, Christopher McBride
  • Publication number: 20190337965
    Abstract: The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1? and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.
    Type: Application
    Filed: July 16, 2019
    Publication date: November 7, 2019
    Applicant: Genentech, Inc.
    Inventors: Jeffrey A. STAFFORD, James M. VEAL, Lynnie Lin TRZOSS, Christopher MCBRIDE